Is CelLBxHealth plc (ANPCY) a Buy, Sell, or Hold?
CelLBxHealth plc
OTC:ANPCY
$0.067 USD
$0 (0.0%)
- Volume
- 20.02K
- Average Volume
- 19.15K
- Market Capitalization
- $21.98M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $
- Year High
- $2.39
- Year Low
- $0.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $
- Current Ratio
- $
| Source | Headline |
|---|---|
|
T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION
New season, "AI at Work: From Promise to Impact," examines where artificial intelligence may create lasting value, where expectations may be too high, and what investors should watch as adoption moves into the real economy BALTIMORE, July 1, 2026 /PRNewswire/ -- The newest season of "The Angle from T. Rowe Price" podcast debuts today, where the global investment management firm and a leader in retirement convenes some of its leading investment professionals to help listeners separate myth from reality about the burgeoning artificial intelligence sector. prnewswire.com - 2026-07-01 09:30:00 |
|
CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease. proactiveinvestors.co.uk - 2026-04-20 06:01:43 |
|
CelLBxHealth joins forces with The Royal Marsden on lung cancer liquid biopsy study
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), a specialist in circulating tumour cell (CTC) analysis, has announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease. proactiveinvestors.co.uk - 2026-04-20 02:30:01 |
